UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 30, 2014
TG Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware (State or Other Jurisdiction of Incorporation) |
001-32639 (Commission File Number)
|
36-3898269 (IRS Employer Identification No.) |
3 Columbus Circle, 15th Floor
New York, New York 10019
(Address of Principal Executive Offices)
(212) 554-4484
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| £ | Written communications pursuant to Rule 425 under the Securities Act. |
| £ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| £ | Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
| £ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
| Item 8.01. | Other Events. |
On May 30, 2014, TG Therapeutics, Inc. (the “Company”) issued a press release announcing clinical results from its ongoing first-in-human Phase I single agent study of TGR-1202, the Company’s oral PI3K-Delta inhibitor and from its ongoing Phase I single agent study of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody. Data from the Phase I clinical studies are being presented at poster sessions during the 50th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. A copy of the press release is being filed as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements And Exhibits. |
| (d) | Exhibits. |
| 99.1 | Press release issued by the Company on May 30, 2014. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TG Therapeutics, Inc. | ||
| (Registrant) | ||
| By: | /s/ Sean A. Power | |
| Sean A. Power Chief Financial Officer | ||
Date: May 30, 2014
INDEX TO EXHIBITS
| Exhibit Number | Description |
| 99.1 | Press release issued by TG Therapeutics, Inc. on May 30, 2014. |